Earnings summaries and quarterly performance for BioCardia.
Executive leadership at BioCardia.
Board of directors at BioCardia.
Research analysts who have asked questions during BioCardia earnings calls.
Joseph Pantginis
H.C. Wainwright & Co.
2 questions for BCDA
Also covers: ARMP, BLRX, BYSI +15 more
Laura Suriel
Alliance Global Partners
2 questions for BCDA
Also covers: GOVX, IMNN, INMB
James Molloy
Alliance Global Partners
1 question for BCDA
Also covers: ABEO, ACXP, AIM +11 more
JK
Jason Kolbert
D Boral Capital
1 question for BCDA
Also covers: CANF, HUMA, IVVD +6 more
Kumaraguru Raja
Brookline Capital Markets
1 question for BCDA
Lander Egaña-Gorroño
H.C. Wainwright & Co., LLC
1 question for BCDA
Recent press releases and 8-K filings for BCDA.
BioCardia to present late-breaking CardiAMP HF trial echocardiography results
BCDA
New Projects/Investments
- BioCardia, Inc. announced on February 3, 2026, that echocardiography data from its CardiAMP Cell Therapy for heart failure has been accepted for a Late Breaking Clinical Trial Oral Presentation.
- The presentation will take place on March 2, 2026, at 2pm EST at the Technology and Heart Failure Therapeutics (THT) Meeting in Boston, Massachusetts.
- The presentation will cover "Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial.".
- The CardiAMP Cell Therapy has been granted FDA Breakthrough designation.
4 days ago
BioCardia Advances CardiAMP Cell Therapy to Formal Clinical Consultation with Japan PMDA
BCDA
New Projects/Investments
- BioCardia has completed a third preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) for its CardiAMP Cell Therapy for Heart Failure with Reduced Ejection Fraction (HFrEF).
- The PMDA will allow BioCardia to advance to formal clinical consultation, which could lead to filing for regulatory approval in Japan if the available data provides sufficient evidence of safety and efficacy.
- The company's CEO noted that data from three completed Phase I, II, and III trials support positive outcomes in significant clinical efficacy endpoints, including improved survival and reduced major adverse cardiovascular events.
- CardiAMP Cell Therapy has been granted FDA Breakthrough designation and is a minimally invasive, catheter-based procedure using a patient's own bone marrow cells.
Dec 16, 2025, 1:00 PM
BioCardia Reports Third Quarter 2025 Financial Results and Business Highlights
BCDA
Earnings
New Projects/Investments
Guidance Update
- BioCardia reported a net loss of $1.5 million for the three months ended September 30, 2025, which decreased from $1.7 million for the same period in 2024.
- The company closed a $6.0 million financing in September 2025, yielding net proceeds of $5.2 million, and reported a cash balance of $5.3 million as of September 30, 2025, providing runway into the second quarter of 2026.
- BioCardia anticipates requesting an FDA meeting on the approvability of the CardiAMP System and submitting for FDA approval of the Helix Transendocardial Delivery Catheter via DeNovo 510(k), both in the fourth quarter of 2025.
- The CardiAMP HF II phase 3 confirmatory trial is actively enrolling patients, and the company had a positive preliminary clinical consultation with Japan's PMDA regarding the CardiAMP Heart Failure Trial results.
Nov 12, 2025, 9:40 PM
BioCardia Reports Q3 2025 Financial Results and Advances Clinical Programs
BCDA
Earnings
Guidance Update
New Projects/Investments
- BioCardia reported a net loss of $1.5 million for the third quarter of 2025, compared to $1.7 million for the same period in 2024, and concluded the quarter with $5.3 million in cash, which is expected to provide a runway into the second quarter of 2026 without additional financing.
- The company is actively engaged in regulatory processes for its CardiAmp system, having completed a positive preliminary clinical consultation with Japan's PMDA and anticipating an FDA meeting request on approvability in Q4 2025.
- Enrollment in the CardiAmp Heart Failure II confirmatory phase III trial is accelerating, with four centers actively enrolling and three having randomized their first patients.
- Positive top-line results from the open-label rolling cohort of the CardiAmp cell therapy (BCDA02) in chronic myocardial ischemia showed patients experienced an average of 80 seconds increased exercise tolerance and an average of 82% reduction in angina episodes at the six-month primary endpoint.
- BioCardia anticipates securing non-dilutive funding for its CardiALLO (BCDA03) allogeneic mesenchymal stem cell therapy program in the first quarter of 2026.
Nov 12, 2025, 9:30 PM
BioCardia Reports Q3 2025 Financial Results and Clinical Milestones
BCDA
Earnings
New Projects/Investments
Guidance Update
- BioCardia, Inc. reported a net loss of $1.5 million for the third quarter of 2025, compared to $1.7 million for the same period in 2024, and ended the quarter with a cash balance of $5.3 million as of September 30, 2025.
- In September 2025, the company closed a $6.0 million financing, with net proceeds totaling $5.2 million, which is actively supporting key initiatives.
- The company anticipates requesting an FDA meeting on the approvability of the CardiAMP System and submitting for approval of its Helix transendocardial delivery catheter via DeNovo 510(k), both in Q4 2025.
- BioCardia's confirmatory CardiAMP HF II phase 3 trial is actively enrolling patients, and the company had a positive preliminary clinical consultation with Japan's PMDA on CardiAMP Heart Failure Trial results.
Nov 12, 2025, 9:10 PM
BioCardia Announces First Patient Enrollment in Phase 3 CardiAMP HF II Clinical Trial
BCDA
New Projects/Investments
Product Launch
- On October 30, 2025, BioCardia, Inc. announced the first patient enrollment at the University of Wisconsin School of Medicine and Public Health in its Phase 3 CardiAMP HF II clinical trial.
- The CardiAMP HF II study is a 250-patient randomized multicenter procedure placebo-controlled trial evaluating the CardiAMP autologous cell therapy for patients with ischemic heart failure with reduced ejection fraction (HFrEF).
- This therapy, which uses a patient's own bone marrow cells, has been granted FDA Breakthrough designation and aims to confirm the safety and efficacy results observed in the prior CardiAMP HF study.
Oct 30, 2025, 12:00 PM
Quarterly earnings call transcripts for BioCardia.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more